ADCP

INmune Bio Inc. Presents Data on INB03’s Role as an Immune Check Point Modulator in the Treatment of High-Risk Breast Cancer at AACR 2024

Retrieved on: 
Monday, April 8, 2024
TNF, MUC4, Alpha globulin, Disease, Macrophage, CD47, LAG3, Breast cancer, TIGIT, Poster, ADCP, TNBC, Vaccine

Boca Raton, Florida, April 08, 2024 (GLOBE NEWSWIRE) --  INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, is presenting data on the use of INB03, a dominant-negative tumor necrosis factor (TNF) inhibitor of soluble TNF (sTNF) in the treatment of high-risk MUC4 expressing HER2+ and triple negative breast cancer (TNBC).  INB03 is shown to decrease T cell and macrophage immune checkpoint proteins (PD1, TIGIT, LAG3, CD47 and SIRPa) in a model immunotherapy resistant HER2+ breast cancer and decrease the metastatic potential of TNBC by downregulating cell surface markers of tumor invasion (MUC4, SNAIL and Vimectin).  The two posters will be presented at the annual American Association of Cancer Research in San Diego on April 8, 2024.

Key Points: 
  • The two posters will be presented at the annual American Association of Cancer Research in San Diego on April 8, 2024.
  • Decreases in T cell and macrophage immune checkpoint proteins were caused by INB03.
  • The authors speculate that these effects could avoid tumor immune evasion to anti-HER2 targeted therapies by reinvigorating the immune infiltrate.
  • Dr. Schillaci, senior author of the study, proposes INB03 is a new class of immunotherapy called a pan immune checkpoint modulator in MUC4 expressing breast cancer.

Allakos Presents Preclinical Data Highlighting Inhibition of MRGPRX2-Mediated Mast Cell Activation with AK006 at AAAAI 2024

Retrieved on: 
Monday, February 26, 2024
Therapy, Allergy, SAN, AAAAI, Macrophage, Food allergy, Inflammation, B cell, Immunoglobulin E, Prurigo nodularis, MRGPRX2, Skin, Annual general meeting, Prurigo, ADCP, Patient, Poster, Abstract, American Academy, Vaccine

SAN CARLOS, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a clinical-stage biotechnology company developing therapeutics that target immunomodulatory receptors present on immune effector cells involved in allergy, inflammatory and proliferative diseases, today announced a poster presentation at the 2024 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting. The poster highlights preclinical data detailing AK006’s mechanism of action and ability to reduce MRGPRX2-induced skin inflammation.

Key Points: 
  • The poster highlights preclinical data detailing AK006’s mechanism of action and ability to reduce MRGPRX2-induced skin inflammation.
  • Inappropriate mast cell activation, via IgE-dependent and IgE-independent pathways, has been implicated in the pathogenesis of multiple inflammatory skin diseases.
  • IgE-dependent mast cell activation has been identified as a pathogenic driver of chronic spontaneous urticaria and food allergy and agents which target this pathway have demonstrated therapeutic activity.
  • More recently, mast cell activation through MRGPRX2, an IgE independent mast cell activation pathway, has been implicated in the pathogenesis of chronic spontaneous urticaria, atopic dermatitis and prurigo nodularis.

Surveying Equipment Market size is set to grow by USD 2.86 billion from 2022-2027, The growth of the UAV market to be a major trend - Technavio

Retrieved on: 
Tuesday, February 6, 2024
ADCP, Growth, Target Corporation, Thales Group, Hexagon AB, GIS, Teledyne Technologies, UCLASS, USD, Raytheon Technologies, GNSS, Challenge, Trimble Inc., Environmental science, Unmanned aerial vehicle, Total, Acquisition, Risk, PASI, Construction, UAV, GPS, Software, Calibration, Surveying

NEW YORK, Feb. 5, 2024 /PRNewswire/ -- The global surveying equipment market size is estimated to grow by USD 2.86 billion from 2022 to 2027, according to Technavio.

Key Points: 
  • NEW YORK, Feb. 5, 2024 /PRNewswire/ -- The global surveying equipment market size is estimated to grow by USD 2.86 billion from 2022 to 2027, according to Technavio.
  • A significant trend in the surveying equipment market is the increasing adoption of UAVs, particularly for civil applications, offering cost-effective and rapid geospatial data acquisition.
  • The Industrial Multiprotocol Gateways Market size is estimated to grow at a CAGR of 9.7% between 2022 and 2027.
  • The field devices calibration services market size is estimated to grow at a CAGR of 4.54% between 2022 and 2027.

MONJUVI (tafasitamab-cxix) Drug Insights and Market Forecasts, 2019-2022 and 2023-2032: Focus on 7MM - United States, Germany, France, Italy, Spain, United Kingdom, and Japan - ResearchAndMarkets.com

Retrieved on: 
Friday, December 15, 2023
Pharmaceutical, Health, Oncology, Health Canada, Research, Immune system, Lenalidomide, European Commission, MHRA, Clinical trial, Civil service commission, Tafasitamab, CD19, ADCC, SWOT, EU4, ADCP, Fine chemical, Vaccine, Pharmaceutical industry, Risk management, DLBCL

This "MONJUVI Drug Insight and Market Forecast - 2032" report provides comprehensive insights about MONJUVI for Diffuse Large B-cell lymphoma (DLBCL) in the seven major markets.

Key Points: 
  • This "MONJUVI Drug Insight and Market Forecast - 2032" report provides comprehensive insights about MONJUVI for Diffuse Large B-cell lymphoma (DLBCL) in the seven major markets.
  • The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities.
  • Further, it also consists of future market assessments inclusive of the MONJUVI market forecast analysis for DLBCL in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in DLBCL.
  • What are the other emerging products available and how are these giving competition to MONJUVI for DLBCL?

INmune Bio Inc. Presents Preclinical Data at SITC 2023 Showing INB03 is an Innate Immune Check Point Inhibitor that Downregulates SIRPα

Retrieved on: 
Monday, October 30, 2023
Neoplasm, PD-L1, Trastuzumab, AD, Therapy, TNF, Macrophage, CD47, Research, Poster, Society for Immunotherapy of Cancer, CD8, Mouse, LAG3, Disease, Breast cancer, ADCP, Microglia, Brain, Tumor microenvironment, Phagocytosis, Safety, DMD, Cancer, Remyelination, Instituto de Biología y Medicina Experimental, Society, TME, MS, Vaccine, Medical imaging, Immunotherapy

Boca Raton, Florida, Oct. 30, 2023 (GLOBE NEWSWIRE) --   INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, is presenting data on the use of INB03, a dominant-negative inhibitor of soluble TNF in the treatment of high-risk MUC4 expressing HER2+ breast cancer. Roxana Schillaci Ph.D. of Instituto de Biología y Medicina Experimental in Buenos Aries, Argentina, will present her work at the 38th annual Society of Immunotherapy in San Diego, California which runs from November 1-4.

Key Points: 
  • INB03 downregulates expression of SIRPα on macrophages promote increased cancer cell death by antibody dependent cellular phagocytosis (ADCP).
  • The poster entitled “INB03: a new immune checkpoint inhibitor that reprograms polarization and promotes ADCP in human macrophages,” shows that INB03 is an innate immune checkpoint inhibitor working through the SIRPα-CD47 pathway to promote ADCP.
  • INB03 downregulates SIRPα expression to eliminate the “don’t eat me signal” and promote ADCP.
  • INB03 neutralizes sTNF, repolarizing tumor protecting M2 macrophages to M1 anti-tumor macrophages, enhances ADCP with trastuzumab, and reduces SIRPα expression.

Claudin 18.2-Targeted Immunotherapy Research Report 2023: Landscape Analysis of Stakeholders, Drug Modalities, Pipeline and Business Opportunities from An Industry Perspective - ResearchAndMarkets.com

Retrieved on: 
Wednesday, September 27, 2023
Health, Pharmaceutical, Incidence, Partnership, ADCC, Bi-specific T-cell engager, TCE, Hook effect, Overalls, Survival, Big Pharma, Business, Research, Appetite, History, Immunotherapy, Zolbetuximab, CDC, Vomiting, CAR, Science, Patient, Corporation, Antibody, Cancer, European, ADCP, Spacecraft, BDL, R, Stomach, GLOW, III, Bispecific monoclonal antibody, Safety, Sales, Vaccine, Pharmaceutical industry, Fine chemical, Risk management, Medical imaging, Dietary supplement

The "Claudin 18.2-Targeted Immunotherapy: A Landscape Analysis of Stakeholders, Drug Modalities, Pipeline and Business Opportunities from An Industry Perspective" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Claudin 18.2-Targeted Immunotherapy: A Landscape Analysis of Stakeholders, Drug Modalities, Pipeline and Business Opportunities from An Industry Perspective" report has been added to ResearchAndMarkets.com's offering.
  • This comprehensive report offers valuable insights into the world of claudin 18.2 (CLDN18.2)-targeted antibody and cell therapy candidates, as of August 2023.
  • You'll delve into the industry landscape surrounding innovative claudin18.2-targeted antibody and cell therapy candidates.
  • The report shines a light on 48 companies actively engaged in research and development within this field, highlighting 68 unique product candidates.

Phanes Therapeutics Announces First Patient Dosed in Phase 1 Study of PT217 for Small Cell Lung Cancer and Other Neuroendocrine Cancers Expressing DLL3

Retrieved on: 
Thursday, September 7, 2023
Carcinoma, CD47, Macrophage, ADCC, ODD, Glomus tumor, Monoclonal antibody, NEPC, Pharmacokinetics, NK, Research, APC, SCLC, DLL3, Patient, SAN, ADCP, FDA, Therapy, Safety, Disease, Pharmaceutical industry

SAN DIEGO, Sept. 7, 2023 /PRNewswire/ -- Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and development in oncology, announced today that the first patient has been dosed in the Phase 1 clinical study (NCT05652686) of PT217, a first-in-class native IgG-like bispecific antibody (bsAb) targeting DLL3 and CD47 for the treatment of small cell lung cancer and other neuroendocrine tumors. PT217 is a common light chain bispecific antibody discovered through Phanes' research engine and was granted orphan drug designation (ODD) for the treatment of small cell lung cancer by the FDA last year.

Key Points: 
  • PT217 is a common light chain bispecific antibody discovered through Phanes' research engine and was granted orphan drug designation (ODD) for the treatment of small cell lung cancer by the FDA last year.
  • The anti-CD47 arm of PT217 is differentiated and has demonstrated minimum binding to human red blood cells while maintaining strong binding activity to CD47 on tumor cells.
  • "Small cell lung cancer is one of the most devastating and aggressive solid tumor cancers with patients lacking effective therapies to treat their disease.
  • PT217 is a product of Phanes' ingenious innovation in creative design of both novel therapeutic approaches and practical technologies," said Dr. Ming Wang, Founder and CEO of Phanes.

Adagene Reports Six Month Financial Results for 2023 and Provides Corporate Update

Retrieved on: 
Thursday, August 31, 2023
Bevacizumab, Senior, ADCC, Neoplasm, Lead, Head, Bioinformatics, GAAP, Information technology, Doctor of Philosophy, Patient, HNSCC, ADCP, Research and development, R, HCC, SAB, CD47, PRS, Therapy, Merck & Co., Net, Cervical cancer, CPS, MSI, ADC, PD-1, PR, Safety, Exercise, AACR, Liver disease, MSS, Roche, Therapeutic index, GenScript Biotech, American Association for Cancer Research, CR, Pembrolizumab, ORR, Renal cell carcinoma, SCC, CRC, RCC, ADS, CMC, Yan Li, Clinical trial, Trae Waynes, Endometrial cancer, Financial toxicity, Poster, Tumor microenvironment, Pharmaceutical industry, Palladium, Medical imaging, Vaccine, Management, Cryptocurrency, Fine chemical, Bank, Legend, Immunoglobulin G, MD, Sanofi, Exelixis

Additionally, Fangyong (Felix) Du, Ph.D, Chief Technology Officer at Adagene since 2020, is stepping down from the board for personal reasons.

Key Points: 
  • Additionally, Fangyong (Felix) Du, Ph.D, Chief Technology Officer at Adagene since 2020, is stepping down from the board for personal reasons.
  • Cash and cash equivalents were US$128.8 million as of June 30, 2023, compared to US$143.8 million as of December 31, 2022.
  • The company uses non-GAAP net loss and non-GAAP net loss per ordinary shares for the period, which are non-GAAP financial measures, in evaluating its operating results and for financial and operational decision-making purposes.
  • The company encourages investors and others to review its financial information in its entirety and not rely on a single financial measure.

Global Bispecific Antibodies Market Report 2023: Rising Interest in Bispecific Antibody Therapeutics Drives Growth - ResearchAndMarkets.com

Retrieved on: 
Wednesday, July 5, 2023
Health, Biotechnology, Zymeworks, Bispecific monoclonal antibody, Monoclonal antibody, Amgen, Antigen, Therapy, Prevalence, ADCC, Roche, Research, Infection, Antibody, CDC, Organization, Janssen Pharmaceuticals, Epitope, Conditional sentence, ADCP, Merck, FDA, Stomach, III, Vaccine, Pharmaceutical industry, Fine chemical, AstraZeneca, Ozoralizumab, Blinatumomab, AK104

Bispecific antibodies (BsAbs) represent a novel class of antibodies that act by simultaneously attaching to two separate / distinct antigens or different epitopes of the same antigen.

Key Points: 
  • Bispecific antibodies (BsAbs) represent a novel class of antibodies that act by simultaneously attaching to two separate / distinct antigens or different epitopes of the same antigen.
  • In the foreseen future, as more such therapeutic candidates move into the clinical stage and / or receive approval, we anticipate the bispecific antibody therapeutics market to witness healthy growth.
  • The increasing prevalence of chronic diseases, such as oncological disorders, autoimmune disorders and infectious diseases, is expected to drive the market for bispecific antibody therapeutics.
  • Driven by the rising interest in R&D activities and growing demand for effective therapeutics, the bispecific antibody therapeutics market is anticipated to witness an annualized growth rate of over 9.5%, during the period 2023-2035.

Phanes Therapeutics Announces First Patient Dosed in Phase 1 Study of PT886 for Advanced Gastric, Gastroesophageal Junction and Pancreatic Adenocarcinomas

Retrieved on: 
Monday, March 20, 2023
Bispecific monoclonal antibody, Pancreatic cancer, CD47, Macrophage, ADCC, ODD, Monoclonal antibody, RECIST, Pharmacokinetics, NK, Trial of the century, APC, Patient, ECOG, SAN, Cancer, ADCP, Neoplasm, Ageing, FDA, Therapy, Safety, Pharmaceutical industry

PT886 was assembled using Phanes' proprietary bispecific antibody platforms PACbody™ and SPECpair™ and was granted orphan drug designation (ODD) for the treatment of pancreatic cancer by the FDA last year.

Key Points: 
  • PT886 was assembled using Phanes' proprietary bispecific antibody platforms PACbody™ and SPECpair™ and was granted orphan drug designation (ODD) for the treatment of pancreatic cancer by the FDA last year.
  • The anti-CD47 arm of PT886 is highly differentiated and has demonstrated minimum binding to human red blood cells while maintains strong binding activity to CD47 on tumor cells.
  • "PT886 targets a validated tumor associated antigen in claudin 18.2 with enhanced anti-tumor activity and broadened tumor killing spectrum through a best-in-class anti-CD47 arm.
  • It is a product of Phanes' ingenious innovation in creative design of both novel therapeutic approaches and practical technologies," said Dr. Ming Wang, Founder and CEO of Phanes Therapeutics.